GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (XCNQ:CMND) » Definitions » Valuation Rank

Clearmind Medicine (XCNQ:CMND) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Clearmind Medicine Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Clearmind Medicine Valuation Rank Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (XCNQ:CMND) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (XCNQ:CMND) » Definitions » Valuation Rank
Comparable Companies
TSXV:MRVL TSX:IPCI XCNQ:GLOW XCNQ:BIOV XCNQ:NOVA XCNQ:NIRV XCNQ:BRAX TSXV:WAVE XCNQ:MBIO TSX:APLI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CMND:USA CWY0:Germany
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Website
https://www.clearmindmedicine.com
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.